Advertisement
IMRX vs SPRB
Which Stock Would AI Choose? Immuneering Corporation (IMRX) vs. Spruce Biosciences (SPRB) Stock Comparison
Key Takeaways
- Immuneering (IMRX) is a clinical-to-late-stage oncology company advancing a lead MEK inhibitor program toward a pivotal Phase 3 trial in first-line pancreatic cancer.
- Spruce Biosciences (SPRB) is a late-stage rare-disease company preparing a Biologics License Application (BLA) for its lead enzyme replacement therapy targeting Sanfilippo Syndrome Type B.
- Both companies are pre-revenue biotech developers with meaningful cash runways, but their catalysts, timelines, and risk profiles differ sharply.
- IMRX carries a larger market capitalization and a broader cash runway (into 2029) versus SPRB's more concentrated, near-term regulatory catalyst in late 2026.
- Relative momentum and analyst positioning lean constructive for both, though each faces distinct clinical, regulatory, and financing risks.
Introduction
This stock comparison examines two development-stage biotechnology companies operating in very different corners of healthcare. IMRX, Immuneering Corporation, is focused on oncology, while SPRB, Spruce Biosciences, targets rare neurological disorders. For traders and investors evaluating relative performance and market positioning, the contrast is instructive: one stock is building toward a large pivotal oncology trial with data years away, while the other is approaching a regulatory filing that could reshape its near-term outlook. Understanding how their catalysts, cash positions, and sentiment signals differ can help readers assess which profile better aligns with their own time horizon and risk tolerance.
IMRX Overview and Recent Performance
Immuneering Corporation is a late-stage clinical oncology company developing a new class of medicines it calls Deep Cyclic Inhibitors. Its lead candidate, atebimetinib, is an oral, once-daily inhibitor of MEK (mitogen-activated protein kinase kinase, a key enzyme in cancer cell signaling pathways). In recent weeks, the company reported updated Phase 2a data showing a 17.3-month median overall survival (mOS, a measure of how long patients live after starting treatment) in first-line pancreatic cancer patients treated with atebimetinib plus chemotherapy, alongside an 82% disease control rate.
These results have supported a pivot toward a global randomized Phase 3 trial, MAPKeeper 301, which is now recruiting patients, with topline data anticipated in mid-2028. Financially, IMRX ended its most recent quarter with roughly $182.7 million in cash and expects its runway to extend into 2029. Analysts have generally maintained Buy or Strong Buy ratings with price targets spanning approximately $12 to $20, reflecting optimism around the program's durability signals. Relative performance has been shaped primarily by clinical data readouts and the advancement toward pivotal-stage development.
SPRB Overview and Recent Performance
Spruce Biosciences is a late-stage biopharmaceutical company focused on rare neurological disorders. Its lead program, tralesinidase alfa (TA-ERT), is an enzyme replacement therapy being developed for Sanfilippo Syndrome Type B (also called MPS IIIB, or mucopolysaccharidosis type IIIB), a pediatric neurodegenerative condition with no approved treatment. Following productive regulatory meetings with the FDA (U.S. Food and Drug Administration), Spruce is preparing a BLA (Biologics License Application, the formal request for approval to market a biologic drug) for TA-ERT, targeted for the fourth quarter of 2026.
Recent market activity has been shaped by a mix of financing and clinical momentum. In April, Spruce closed an underwritten public offering raising approximately $69 million in gross proceeds, bringing its cash balance to roughly $107.3 million as of late April and extending its runway into the second half of 2027. The company also secured up to $50 million in term loans and has been building out a commercial leadership team ahead of a potential launch. Long-term data presented in recent months supported TA-ERT's potential as a disease-modifying therapy, contributing to a generally constructive, though volatility-prone, sentiment environment.
Trending AI Robots
For investors seeking a more systematic approach to names like these, Tickeron's Trending AI Robots page offers a curated view of the platform's AI-driven trading tools. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only the most suitable performers for current market conditions earn a place in the Trending section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the specific sets of tickers they monitor, so no two are alike. The curated list is designed to help traders quickly identify the bots currently demonstrating the strongest alignment with prevailing market dynamics. Exploring the Trending AI Robots page can offer a practical, data-driven way to complement your own research on stocks such as IMRX and SPRB.
Head-to-Head Comparison
The clearest contrast between these two stocks lies in their development stage and catalyst timing. IMRX is entering a large, multi-year Phase 3 oncology trial with pivotal data not expected until 2028, backed by a comparatively deep cash position. Its investment thesis rests on the breadth of a potential first-line pancreatic cancer opportunity and a differentiated mechanism of action. SPRB, by contrast, has a nearer-term binary event: a planned BLA submission and potential accelerated approval decision, with commercialization efforts already underway.
Risk profiles also diverge. IMRX faces long execution risk and substantial spending over an extended timeline, while SPRB carries concentrated regulatory risk and a shorter cash runway that required dilutive financing. Sector exposure differs as well: oncology versus rare pediatric neurology. Market sentiment around IMRX has been anchored by encouraging survival data and analyst support, while SPRB's narrative is tied more directly to regulatory and commercial-readiness milestones. Neither company currently generates product revenue, so both are evaluated primarily on pipeline progress and balance-sheet durability.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst proximity, and relative positioning, Tickeron's AI would likely view SPRB as the more compelling near-term candidate, given its defined regulatory catalyst and clearer path to a potential value inflection in the coming quarters. At the same time, IMRX may appeal more on stability and balance-sheet strength, with a longer runway and broad clinical momentum. The most probable AI-favored outcome would lean toward SPRB on catalyst timing while acknowledging IMRX's more durable funding profile, underscoring that each stock serves a different investor objective rather than offering a one-size-fits-all winner.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMRX is a StrongBuy and SPRB is a StrongBuy.
IMRX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 13, 2026
IMRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 38 cases where IMRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMRX's RSI Indicator exited the oversold zone, 23 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 59 cases where IMRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for IMRX just turned positive on October 20, 2026. Looking at past instances where IMRX's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.
Following a +2.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMRX advanced for three days, in 224 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMRX as a result. In 80 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IMRX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. IMRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.269) is normal, around the industry mean (2.988). P/E Ratio (-4.022) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SPRB in +5.77% Uptrend, rising for three consecutive days on October 21, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SPRB advanced for three days, in 202 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SPRB's RSI Indicator exited the oversold zone, 19 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 70 cases where SPRB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for SPRB just turned positive on October 21, 2026. Looking at past instances where SPRB's MACD turned positive, the stock continued to rise in 31 of 39 cases over the following month. The odds of a continued upward trend are 79%.
SPRB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
SPRB moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SPRB crossed bearishly below the 50-day moving average on September 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for SPRB entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.467) is normal, around the industry mean (2.988). P/E Ratio (-1.112) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (53.476) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SPRB | ||
|---|---|---|
OUTLOOK RATING 1..100 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 57 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 81 | |
P/E GROWTH RATING 1..100 | 34 | |
SEASONALITY SCORE 1..100 | 24 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| IMRX | SPRB | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 68% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 90% | N/A |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Advances ODDS (%) | 2 days ago 89% | 2 days ago 80% |
| Declines ODDS (%) | 9 days ago 90% | 9 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 89% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMRX’s FA Score shows that 1 FA rating(s) are green while SPRB’s FA Score has 0 green FA rating(s).
- IMRX’s FA Score: 1 green, 4 red.
- SPRB’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMRX’s TA Score shows that 5 TA indicator(s) are bullish while SPRB’s TA Score has 5 bullish TA indicator(s).
- IMRX’s TA Score: 5 bullish, 3 bearish.
- SPRB’s TA Score: 5 bullish, 4 bearish.
Price Growth
IMRX (@Biotechnology) experienced а +9.36% price change this week, while SPRB (@Biotechnology) price change was +9.62% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.04%. For the same industry, the average monthly price growth was -18.13%, and the average quarterly price growth was -15.32%.
Reported Earning Dates
IMRX is expected to report earnings on Nov 11, 2026.
SPRB is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (-1.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IMRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMRX has been loosely correlated with SPRB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if IMRX jumps, then SPRB could also see price increases.
| Ticker / NAME | Correlation To IMRX | 1D Price Change % | ||
|---|---|---|---|---|
| IMRX | 100% | +0.27% | ||
| SPRB - IMRX | 52% Loosely correlated | +3.64% | ||
| ACRV - IMRX | 49% Loosely correlated | +1.67% | ||
| CRMD - IMRX | 47% Loosely correlated | +2.91% | ||
| RAPP - IMRX | 41% Loosely correlated | -14.67% | ||
| LXEO - IMRX | 40% Loosely correlated | -0.66% | ||
More | ||||
SPRB and
Correlation & Price change
A.I.dvisor indicates that over the last year, SPRB has been loosely correlated with IMRX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRB jumps, then IMRX could also see price increases.
| Ticker / NAME | Correlation To SPRB | 1D Price Change % | ||
|---|---|---|---|---|
| SPRB | 100% | +3.64% | ||
| IMRX - SPRB | 52% Loosely correlated | +0.27% | ||
| MLEC - SPRB | 51% Loosely correlated | +3.75% | ||
| ANRO - SPRB | 37% Loosely correlated | -4.47% | ||
| FLNA - SPRB | 36% Loosely correlated | -4.24% | ||
| COYA - SPRB | 36% Loosely correlated | -1.66% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TOT | 24.29 | 0.16 | +0.68% |
| LionShares U.S. Equity Total Return ETF (TOT) | |||
| MVFG | 34.37 | 0.06 | +0.17% |
| Monarch Volume Factor Global Unconstrained Index ETF (MVFG) | |||
| EVPF | 48.23 | -0.07 | -0.15% |
| Eaton Vance Preferred Securities and Income ETF (EVPF) | |||
| HFRO | 6.11 | -0.01 | -0.16% |
| Highland Opportunities and Income Fund | |||
| XLRE | 42.06 | -0.32 | -0.76% |
| State Street Real Estate Select Sector SPDR ETF (XLRE) | |||